

Sarabjot Pabla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6102724/publications.pdf>

Version: 2024-02-01

34
papers

552
citations

1039406

9
h-index

887659

17
g-index

34
all docs

34
docs citations

34
times ranked

1029
citing authors

#	ARTICLE	IF	CITATIONS
1	Visceral Obesity in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3450.	1.7	1
2	Immune profiling and immunotherapeutic targets in pancreatic cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 119-119.	0.7	15
3	Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response. <i>Biomarker Research</i> , 2021, 9, 56.	2.8	14
4	Visceral Obesity Promotes Lung Cancer Progression—Toward Resolution of the Obesity Paradox in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1333-1348.	0.5	27
5	Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. <i>Annals of Oncology</i> , 2021, 32, 1626-1636.	0.6	86
6	Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100254.	0.6	3
7	A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. <i>PLoS ONE</i> , 2021, 16, e0260089.	1.1	13
8	Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1324.	1.1	0
9	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. <i>OncolImmunology</i> , 2020, 9, 1773200.	2.1	10
10	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
11	Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. , 2019, 7, 27.		66
12	Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2181-2187.	0.5	23
13	Identification of targets for prostate cancer immunotherapy. <i>Prostate</i> , 2019, 79, 498-505.	1.2	25
14	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 95-109.	1.2	50
15	Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein. <i>International Journal of Molecular Sciences</i> , 2018, 19, 577.	1.8	13
16	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111
17	PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. <i>OncolImmunology</i> , 2018, 7, e1460298.	2.1	14
18	Comprehensive immune and mutational profile of melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 182-182.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Immune deserts: Correlation of low CD8 gene expression with non-response to checkpoint inhibition.. Journal of Clinical Oncology, 2018, 36, 23-23.	0.8	1
20	Effect of CTLA-4 overexpression on response to ipilimumab in melanoma.. Journal of Clinical Oncology, 2018, 36, 190-190.	0.8	1
21	Long-amplicon TCR β repertoire sequencing to reveal human T-cell receptor variable gene polymorphism: Implications for the prediction and interpretation of immunotherapy outcome.. Journal of Clinical Oncology, 2018, 36, 129-129.	0.8	0
22	Correlation of lung cancer mutational profile with immune profile.. Journal of Clinical Oncology, 2018, 36, 146-146.	0.8	1
23	Combination immunotherapy selection for non-PD-1 axis driven tumors.. Journal of Clinical Oncology, 2018, 36, e15058-e15058.	0.8	0
24	Combination immunotherapy selection for PD-1 axis driven tumors.. Journal of Clinical Oncology, 2018, 36, e15024-e15024.	0.8	0
25	Validation of a prognostic 53-immune-gene panel in stage II/III melanoma.. Journal of Clinical Oncology, 2018, 36, 9576-9576.	0.8	0
26	Abstract 2267: A novel method for classification of microsatellite instability (MSI) using the OncoPrint Tumor Mutation Load assay. , 2018, , .		0
27	Abstract 5070: Chemokine expression signatures in infiltrated vs non-infiltrated tumors. , 2018, , .		0
28	Abstract 4526: Predicting response: PD-L1 biomarker testing by IHC and RNA-seq. Cancer Research, 2018, 78, 4526-4526.	0.4	1
29	Abstract 4668: Evidence for antigen-driven TCRB chain convergence in the tumor infiltrating T cell repertoire of 85 research subjects with melanoma. , 2018, , .		1
30	Abstract 3679: PD-L1 driven excluded phenotype in melanoma. , 2018, , .		0
31	Algorithmic prediction of response to checkpoint inhibitors: Hyperprogressors versus responders.. Journal of Clinical Oncology, 2017, 35, 11565-11565.	0.8	3
32	Abstract 620: Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient. , 2017, , .		0
33	Abstract 1625: NGS reveals specimen characteristics have minimal impact on immune gene expression signature. , 2017, , .		0
34	Abstract 1626: Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification. , 2017, , .		0